Acute Management of Atrial Fibrillation From Emergency Department to Cardiac Care Unit

被引：5
作者：
Beck, Hiroko [1 ]
See, Vincent Y. [1 ]
机构：
[1] Univ Maryland, Med Ctr, Sch Med, Cardiac Electrophysiol Sect,Div Cardiol,Dept Med, Baltimore, MD 21201 USA
来源：
CARDIOLOGY CLINICS | 2012年 / 30卷 / 04期
关键词：
Atrial fibrillation; Cardioversion; Rate control; Rhythm control; Stroke; Thromboembolism; Arrhythmia; Anticoagulation; EXPERT CONSENSUS STATEMENT; NEWER ORAL ANTICOAGULANTS; LONG-TERM OUTCOMES; RISK-FACTORS; FOLLOW-UP; CATHETER ABLATION; RHYTHM CONTROL; TASK-FORCE; PREVENT THROMBOEMBOLISM; SURGICAL ABLATION;
D O I：
10.1016/j.ccl.2012.07.007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Atrial fibrillation (AF) is the most common tachyarrhythmia encountered in clinical practice. One-third of hospitalizations in the United States are attributed to AF, with increasing rates in the past decade. Significant morbidity and mortality, including similar to 15% to 20% of all ischemic strokes, result from AF. AF is associated with many causes and comorbidities. Hallmarks of acute AF management are accurate diagnosis, clinical stabilization, symptom relief through rate or rhythm control, thromboembolic stroke risk modification, and treatment of underlying causes. Meticulous and individualized acute evaluation based on these goals facilitates successful transition to long-term collaborative optimization of outcomes.
引用
收藏
页码：567 / +
页数：24
相关论文
共 77 条
[1]  
Douglas PS, 2011, J AM COLL CARDIOL
[2]   Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket'' approach [J].
Alboni, P ;
Botto, GL ;
Baldi, N ;
Luzi, M ;
Russo, V ;
Gianfranchi, L ;
Marchi, P ;
Calzolari, M ;
Solano, A ;
Baroffio, R ;
Gaggioli, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (23) :2384-2391
[3]   Should Newer Oral Anticoagulants Be Used as First-Line Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation and Risk Factors for Stroke or Thromboembolism? New Oral Anticoagulants Should Not Be Used as First-Line Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation [J].
Ansell, Jack .
CIRCULATION, 2012, 125 (01) :165-170
[4]   Impact of atrial fibrillation on the risk of death [J].
Benjamin, EJ ;
Wolf, PA ;
D'Agostino, RB ;
Silbershatz, H ;
Kannel, WB ;
Levy, D .
CIRCULATION, 1998, 98 (10) :946-952
[5]   Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: A retrospective analysis [J].
Berger, M ;
Schweitzer, P .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (12) :1545-+
[6]   Atrioventricular junction ablation and pacemaker implant for atrial fibrillation: still a valid treatment in appropriately selected patients [J].
Betts, Timothy R. .
EUROPACE, 2008, 10 (04) :425-432
[7]   HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for personnel, policy, procedures and follow-up [J].
Calkins, Hugh ;
Brugada, Josep ;
Packer, Douglas L. ;
Cappato, Riccardo ;
Chen, Shih-Ann ;
Crijns, Harry J. G. ;
Damiano, Ralph J., Jr. ;
Davies, D. Wyn ;
Haines, David E. ;
Haissaguerre, Michel ;
Lesaka, Yoshito ;
Jackman, Warren ;
Jais, Pierre ;
Kottkamp, Hans ;
Kuck, Karl Heinz ;
Lindsay, Bruce D. ;
Marchlinski, Francis E. ;
McCarthy, Patrick M. ;
Mont, J. Lluis ;
Morady, Fred ;
Nademanee, Koonlawee ;
Natale, Andrea ;
Pappone, Carlo ;
Prystowsky, Eric ;
Raviele, Antonio ;
Ruskin, Jeremy N. ;
Shemin, Richard J. .
EUROPACE, 2007, 9 (06) :335-379
[8]  
Calkins H, 2012, HEART RHYTHM, V9, P632, DOI 10.1016/j.hrthm.2011.12.016
[9]  
Camm AJ, 2010, EUROPACE, V12, P1360, DOI [10.1093/europace/euq350, 10.1093/eurheartj/ehq278]
[10]   Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial [J].
Connolly, S. ;
Pogue, J. ;
Hart, R. ;
Pfeffer, M. ;
Hohnloser, S. ;
Chrolavicius, S. ;
Yusuf, S. .
LANCET, 2006, 367 (9526) :1903-1912
12345678